STAT+: States are ramping up scrutiny of health transactions, as more provider groups look for buyers
UnitedHealth Group’s Optum has bought an untold number of physician practices over the years. It…
Category: Medicine
Opinion: How much personal health information does King Charles owe the public?
On Feb. 5, Buckingham Palace shared the news that King Charles had started treatment for…
.jpg)
STAT+: FTC doubles down in Welsh Carson anesthesia case to limit private equity’s physician buyouts
Lina Khan’s Federal Trade Commission is eager to make Big Physician a lot smaller. Last…
Opinion: What STAT readers think about Aduhelm, CTE and the Super Bowl, and more
STAT now publishes selected Letters to the Editor received in response to First Opinion essays…
A neuropsychologist clarifies science on aging and memory in wake of Biden special counsel report
What is the relationship between aging, memory loss, and overall cognition? That’s a matter of…
STAT+: Major generic maker Aurobindo cuts production at a key plant amid concerns over shortages
Aurobindo, which is one of the largest generic drug makers, has halted some production at…
STAT+: Senators start work on Medicare physician payment reform
WASHINGTON — A bipartisan group of senators is starting work on legislation to reform how…
Does Moderna’s RSV vaccine lose efficacy faster than others?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about a U.S. vaccine panel, an abortion pill, and much more
And so, another working week will soon draw to a close. Not a moment too…
Opinion: Former U.S. surgeons general: The U.S. should ban menthol cigarettes
As former U.S. surgeons general, we call on the Biden administration to immediately finalize Food…
Opinion: Contact sports cause CTE. So why are Americans watching more football than ever?
In January 2023, minutes after Damar Hamlin collapsed on the field following a tackle, my cellphone was…
STAT+: Lasers, cardiology, clinical trials: 2023’s top private equity targets
By some measures, private equity investment lagged in 2023, a year marked by growing distress…
STAT+: A junior scientist. A prominent oncologist. Now, a clash at MD Anderson over who gets research credit
Three years ago, Jamie Lin, an early-career nephrologist at MD Anderson Cancer Center, made findings…
STAT+: Key House Republican on health care plans exit from Congress
WASHINGTON — Rep. Cathy McMorris Rodgers, the chair of a crucial House committee that handles…
.jpg)
STAT+: Senate Democrats push for stronger rules around AI in Medicare Advantage
Senate Democrats on Thursday said Medicare should take more urgent and aggressive action to prevent…
AI in medicine, detangling hype, and Icelandic DNA
Has AI really solved biology? What can machines teach us about medicine? And what’s a…
In a showy hearing, Bernie Sanders gets few answers about lower drug prices
WASHINGTON — Call it Sen. Bernie Sanders’ prescription drug pricing theater. The hearing, featuring Merck…
Higher naloxone doses have no impact on overdose survival, study shows
People receiving a double dose of naloxone are no more likely to survive an opioid…
STAT+: A looming cancer vaccine test for Gritstone Bio, and pushback about Novartis-MorphoSys
This week, I address pushback I received on my Novartis-MorphoSys column. But first, a preview…
STAT+: A looming cancer vaccine test for Gristone Bio, and pushback on my Novartis-MorphoSys take
This week, I address pushback I received on my Novartis-MorphoSys column. But first, a preview…
Studies cited in abortion pill case are retracted due to flaws and conflicts of interest
A medical journal has retracted two studies claiming to show the harms of the abortion…
Gilead sours on the ‘don’t eat me’ business
Want to stay on top of the science and politics driving biotech today? Sign up to get…
New pharma CEOs in the hot seat
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
STAT+: Pharmalittle: We are reading about Catalent concerns, a congressional hearing, and more
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: As Medicare drug pricing negotiations begin, AstraZeneca stays mum on government’s offer
LONDON — Medicare’s first-ever drug pricing negotiations are officially underway. But neither government officials nor…
Opinion: Moving from crisis response to crisis prevention in U.S. mental health systems
Despite widespread promises of reform after the murder of George Floyd in 2020, in 2023,…
STAT+: More than half the slots on a key vaccine advisory panel are vacant. Where’s HHS?
A critical government advisory committee charged with charting U.S. vaccination policy appears to be atrophying,…
Could testosterone be a useful treatment for menopause?
The world may be getting over the idea that men are from Mars and women…
Can exercise help treat long Covid? New study finds patients improve with self-paced approach
Fatigue leads the list of persistent problems experienced by people with long Covid — which…
STAT+: A gene therapy designed to heal skin wounds helped preserve a boy’s vision
In the clinical trial, the gene therapy seemed to be helping the boy’s skin wounds…
STAT+: Government warns Medicare Advantage insurers not to deny care based on AI
In recent months, the federal government has repeatedly told Medicare Advantage insurers that they cannot…
STAT+: Mystery of allergic memory gets closer to answer: a rare group of B cells
Maria Curotto de Lafaille’s lab was trying to make human plasma cells in a dish….
STAT+: Years into an addiction crisis, a med school lecture still minimized opioid risks
Amid ongoing concern over opioid addiction, a university in Florida has been criticized for allowing…
The GLP-1 panic is alive and well
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about worries over a Novo deal, a PBM bill, and more
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
STAT+: RayzeBio co-founder, industry veterans launch new biotech VC with $310 million
Three biotech VC veterans, including one of the co-founders of radiopharma success story RayzeBio, are…
STAT+: AI can speed up drug discovery but don’t expect it to cure cancer, yet
David Reese calls it a “hinge moment” — the turning point when biotech and big…
Opinion: AI assurance labs intended to test health care technology have an equity problem
As leaders across federal agencies swiftly advance regulations for AI in health care, one proposal…
STAT+: Health care developers are impressed by Apple Vision Pro, but they aren’t diving head first
Apple has long touted the potential of the iPhone and Apple Watch to help people…
STAT+: House panel passes key PBM reform for sliver of commercial market
WASHINGTON — A House panel passed a bipartisan bill to ban drug middlemen from charging…
STAT+: Why Eli Lilly’s earnings didn’t quite live up to the hype
Eventually, the luckiest companies get to deal with a very particular problem: what to do…
STAT+: Medicare threatens to pull funding from HCA’s embattled Mission Hospital
Five years after investor-owned HCA Healthcare took over an esteemed nonprofit hospital in North Carolina,…
STAT+: Colombia proceeds with plans to issue a compulsory license for an HIV medicine sold by GSK’s ViiV
The Colombian government has taken a significant step toward issuing a compulsory license for a…
Opinion: Aduhelm was a mess — and it could happen again
Last week, Biogen announced it will cease both the study and sale of Aduhelm, its…
CDC and social media: The new misinformation war
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
STAT+: Why Novartis is going to walk away from its acquisition of MorphoSys
Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The…
Vertex still knows how to do what it does best
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about a lawsuit against J&J, Express Scripts dealings, and more
Top of the morning to you, and a fine one it is. Clear blue skies…
STAT+: Eli Lilly reports tirzepatide MASH success during Q4 earnings
The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve…
Supreme Court to weigh whether Covid misinformation is protected speech
WASHINGTON — As social media sites were flooded with misleading posts about vaccine safety, mask…